Prion Protein: The Molecule of Many Forms and Faces

Valerija Kovač and Vladka Ćurin Šerbec*

Centre for Immunology and Development, Blood Transfusion Centre of Slovenia, Šlajnerjeva 6, SI-1000 Ljubljana, Slovenia; valerija.kovac@ztm.si
* Correspondence: vladka.curin@ztm.si

Abstract: Cellular prion protein (PrPC) is a glycosylphosphatidylinositol (GPI)-anchored protein most abundantly found in the outer membrane of neurons. Due to structural characteristics (a flexible tail and structured core), PrPC interacts with a wide range of partners. Although PrPC has been proposed to be involved in many physiological functions, only peripheral nerve myelination homeostasis has been confirmed as a bona fide function thus far. PrPC misfolding causes prion diseases and PrPC has been shown to mediate β-rich oligomer-induced neurotoxicity in Alzheimer’s and Parkinson’s disease as well as neuroprotection in ischemia. Upon proteolytic cleavage, PrPC is transformed into released and attached forms of PrP that can, depending on the contained structural characteristics of PrPC, display protective or toxic properties. In this review, we will outline prion protein and prion protein fragment properties as well as overview their involvement with interacting partners and signal pathways in myelination, neuroprotection and neurodegenerative diseases.

Keywords: prion protein; prion protein fragments; neuroprotection; myelination; ischemic stroke; neurodegenerative disease

1. Introduction

Prion protein (PrP) is a highly conserved ubiquitous glycoprotein. It exists in two forms; the normal or cellular isoform, PrPC, and the disease-associated infectious isoform or scrapie PrP, PrPSc. The pathological role of PrPSc has been extensively studied in prion disease and has been reviewed in several papers [1–3]. PrPC is expressed in a variety of different organs and tissues with high expression levels in the central and peripheral nervous systems. It is abundantly present on the cell surface of neurons [4–6] and has been shown to be involved in many physiological mechanisms. The function of the protein remains to be elucidated; nevertheless, intensive studies link PrPC to myelin homeostasis [7], neuroprotection [8,9], the circadian rhythm [10,11], metal ion homeostasis [12,13], mitochondrial homeostasis [14] and intercellular signaling [6,15,16]. In neurons, PrPC is present in the presynaptic and postsynaptic compartments of axon terminals where it is involved in anterograde and retrograde axonal transport [17–20]. PrPC is cleaved at the cell membrane by proteases, forming released and attached forms. In recent years, prion protein and prion protein released forms have received attention in correlation with neuroprotection in neurodegenerative diseases. In this review, we present prion protein and prion protein released forms, summarize their involvement in myelination, neuroprotection and neurodegenerative diseases and discuss the most recent discoveries in this field.

2. Prion Protein

Mature human PrPC is composed of a flexible unstructured N-terminal domain (amino acid residues 23–120) and a structured C-terminal domain (amino acid residues 121–231). It is anchored to the cell membrane with a glycosylphosphatidylinositol (GPI) anchor [21,22]. The flexible N-terminal domain contains an octarepeat region whereas the structured domain consists of three α-helices, two β-sheets, a disulfide bond connecting cysteines 179 and 214 and two N-glycans on amino acid residues 181 and 197 [23,24] (Figure 1).
PrPC can transform into a β-sheet-rich isoform PrPSc, which is prone to autocatalytic conversion and aggregation into insoluble aggregates [22,25,26]. An abnormal accumulation of the pathologic protein in the brain can cause the development of transmissible spongiform encephalopathies (TSEs), also known as prion diseases. Prion diseases include Creutzfeldt–Jakob disease (CJD), Gerstmann–Sträussler–Scheinker syndrome (GSS), familial insomnia (FFI) and kuru in humans, bovine spongiform encephalopathy in cattle, scrapie in goats and sheep and chronic wasting disease in cervids. All prion diseases are rare fatal neurodegenerative disorders. The clinical and neuropathological features of prion diseases in humans are similar to those of Alzheimer’s disease (AD) such as rapid memory loss and loss of brain function as well as dementia, spongiform deformation of the brain, personality changes and difficulties with movement [15,27]. Although prion diseases occur due to the accumulation of toxic PrPSc aggregates in the brain, the mechanism that underlies the conversion of PrPC to PrPSc and the development of prion disease remains an unknown. Apart from being a substrate for the development of prion diseases, PrPC can serve as a receptor for cytotoxic amyloid-β (Aβ) oligomers [20,28] and toxic soluble aggregates of tau protein in AD and other tauopathies [29,30]. There are also opposing studies on PrPC binding of α-synuclein (α-syn) oligomers in Parkinson’s disease (PD) and other synucleinopathies, opening the debate on the role of PrPC in toxicity of α-synuclein [30–33].

3. Prion Protein Fragments

PrPC can undergo four posttranslational cleavages, forming PrP fragments (Figure 1). The α-cleavage and β-cleavage occur within the unstructured N-terminal domain whereas the γ-cleavage and PrP shedding occur within the structured C-terminal domain. Apart from the mentioned cleavages, PrPC has been cleaved under experimental conditions with phospholipase C, which cleaved PrPC within the GPI anchor [34,35]. The site of cleavage, length of fragment and membrane attachment allow fragments to take part in various mechanisms.

Figure 1. Schematic presentation of PrPC with associated cleavages. Mature PrPC is approximately 210 amino acids long. The flexible unstructured N-terminal part (residues 23–120) contains the octapeptide repeat region (OR, purple) whereas the highly structured C-terminal part (residues 121–231) is composed of three α-helices (green), two β-sheets (orange), a disulfide bond, two N-glycans (CHO; positions 181 and 197) and a C-terminal GPI anchor. PrP can undergo four cleavages: α-cleavage (cleavage site position 111/112); β-cleavage (cleavage site position 89/90); γ-cleavage (cleavage site presumably between positions 170–120); and shedding (near the C-terminus of PrP). Cleavages result in released (N1, N2, N3, shed PrP) and attached (C1, C2, C3) fragments of PrPSc.
3.1. α-Cleavage

The α-cleavage is the most studied cleavage of PrP\textsubscript{C}. It occurs under physiological conditions in the central hydrophobic region of mature PrP\textsubscript{C} (amino acid residues 105–120 in human sequence 111/112) \cite{36–38} (Figure 1). The cleavage releases an ~11 kDa fragment N1 whereas the ~18 kDa part C1 remains attached to the cell membrane by the GPI anchor \cite{36,39}. For now, there is no unique enzyme responsible for the α-cleavage \cite{24,40}.

Although cleavage sites have been determined with respect to species, the α-cleavage is tolerant to sequence variation in this region as long as its hydrophobicity remains preserved \cite{38}. Studies have shown that α-cleavage in the human brain, mouse models and neuronal cultures occurs in the presence of enzymes ADAM10 and ADAM17 \cite{41–43}. ADAM10 contributes to a constitutive N1 production whereas ADAM17 mainly participates in N1 formation upon stimulation \cite{44,45}. ADAM8 has also been shown to cleave PrP\textsubscript{C} to form N1 and C1 in muscles \cite{46}. A role of ADAM8, ADAM10 and ADAM17 in the α-cleavage has also been supported in a biophysical study \cite{47}. Fragment N1 has a relatively low stability; nevertheless, it was found to be present in body fluids, tissue homogenates or cell culture supernatants \cite{39,48,49}. The cleavage was initially thought to take place in acidic endosomal compartments \cite{50,51} but later studies demonstrated that the α-cleavage occurs during the vesicular trafficking of PrP\textsubscript{C} along the secretory pathway \cite{52,53}. The α-cleavage uses PrP\textsubscript{C} as a substrate, leading to its reduction of the cell surface. As PrP\textsubscript{C} is also a substrate for prion replication and a key mediator of toxicity in prion diseases, AD and other neurodegenerative diseases, the cleavage has a positive biological effect. The flexible N-terminal part of PrP\textsubscript{C} is essential for the interaction of the protein with the binding partners that regulate PrP\textsubscript{C} uptake in trafficking \cite{54,55}. Lacking N1, C1 forms complexes on the cell membrane \cite{56} and is more stable and persistent at the cell surface than PrP\textsubscript{C} \cite{50}. Fragment C1 can be cleaved at the cell surface and released into the extracellular space \cite{57}. C1 was found to inhibit prion replication in mice \cite{58,59} whereas fragment N1 is neuroprotective \cite{60,61}; the absence of the α-cleavage is toxic for both cells and mice \cite{47,62}.

3.2. β-Cleavage

The β-cleavage takes place at the end of the octapeptide repeat region N-terminal of the α-cleavage site. The β-cleavage is mostly observed under pathological conditions and is similar to the α-cleavage. It seems to act protectively. It takes place around amino acid residue 90, forming fragment N2 (~9 kDa) and fragment C2 (~20 kDa) \cite{36,37,48,63} (Figure 1). The β-cleavage of PrP\textsubscript{C} is mediated by reactive oxygen species (ROS) \cite{37,63–66}. By removing ROS, the cleavage protects cells from oxidative stress \cite{65}. Apart from ROS, the β-cleavage is induced by calpains \cite{67}, lysosomal proteases \cite{68,69} or even ADAM8 \cite{47}. Proteinase K cleaves the protease-resistant core of PrP\textsubscript{Sc} (PrP\textsubscript{27–30}) near position 90, creating a fragment with a length similar to C2. Similar to fragment C1, fragment C2 can also be shed from the cell surface \cite{70}. The formation of such a fragment indicates that proteases involved in the β-cleavage could also be involved in the cellular attempts to break down PrP\textsubscript{Sc} \cite{71,72}.

3.3. γ-Cleavage

The most recently discovered protease cleavage of PrP\textsubscript{C} is the γ-cleavage. The cleavage site in PrP\textsubscript{C} remains to be determined but the sizes of the released fragment N3 (~20 kDa) and GPI-anchored fragment C3 (~5 kDa) suggest that protein cleavage occurs in the region between amino acid residues 170 and 200 \cite{73,74} (Figure 1). Studies indicate that the γ-cleavage occurs late in the secretory pathway on an unglycosylated protein in the presence of members of the matrix metalloproteases (MMP) family \cite{73}. The reason the γ-cleavage occurs only on unglycosylated PrP\textsubscript{C} is proposed to be due to the steric hindrance of proteases by glycans in the proximity of the proposed cleavage site \cite{40,75}. The γ-cleavage has been found to exist in different species, tissues and cell culture models.
The determination of its role requires further study although an indication of increased amounts of fragment C3 in a CJD brain may lead to a possible pathogenic significance [73].

3.4. Shedding of Prion Protein

There is also an important cleavage of PrP in proximity to the C-terminus. The cleavage sheds PrP into the extracellular space, leaving a small number of amino acid residues on the cell surface. The cleavage was described in early research [35,39,76,77] but has received more attention in recent years due to the involvement of shed PrP in diseases [40,63,78–83]. Similar to the α-cleavage, the shedding of PrP occurs in the presence of enzymes from the ADAM family. In vitro and in vivo experiments suggest that ADAM9 and ADAM10 are involved in the process of cleavage and the shedding of PrP [47,84–86] where ADAM10 is the primary sheddase for PrP and ADAM9 is the modulator of ADAM10 activity [24]. Shed PrP was first determined in hamsters. In the prion-infected brain of hamsters, shed PrP represented approximately 15% of the PrPSc molecules [76]. A further analysis showed that ADAM10 cleaved shed PrP between Gly228 and Arg229 and formed shed PrP that terminated at Gly228 [84]. An analysis exploring the cleavage site profile of ADAM10 revealed that cleavage is not induced by a unique sequence [87]. Consequently, the ADAM10 protease can produce variants of shed PrP depending on the protein sequence and conformation. Jansen and coworkers described the existence of unanchored PrP forms ending with Tyr225 and Tyr226 in patients with prion disease [88]. The authors characterized two patients with prion disease who carried stop mutations at positions Y226X and Q227X and expressed the respective forms. Using a monoclonal antibody V5B2 [89] that specifically binds to a fragment of PrP ending with Tyr226, we concurrently described the existence of a free form of PrP named PrP226* [90–94]. The distribution of PrP226* in the human brain has been associated with the distribution of PrPSc [90,94]. Due to the existence of more than one shed form, we hypothesized that the proteolytic site in the human sequence is not exclusively located between amino acid residues 228 and 229 but is located in the proximity of the C-terminus [95] (Figure 1). Recently, Linsenmeier et al. published a comprehensive study on the mechanism stimulating PrPC proteolytic shedding [81]. Using animal models and controls, they showed that PrP shedding negatively correlates with prion conversion and that shed PrP is abundantly present in amyloid plaques. They also studied the influence of the binding of PrP-directed antibodies to PrPC in relation to shedding propensity. The binding of whole anti-PrP antibodies to the C-terminal structured domain of PrPC or single-chain antibody derivatives, directed towards repetitive epitopes within the octarepeat region of the N-terminal domain stimulated shedding, when the binding of whole anti-PrP antibodies to the octarepeat region of the N-terminal domain locked the N-terminal domain structure and evoked PrPC surface clustering, endocytosis and degradation in lysosomes [81].

4. Prion Protein and Myelination

PrPC is abundantly expressed in the central nervous system (CNS) and in the peripheral nervous system [4,5]. Studies in primate brains, rodent brains and transgenic mice showed that it is enriched along axons and in presynaptic terminals where it is involved in anterograde and retrograde axonal transport [4,17,18,96–98]. Deletions in the PrPC α-cleavage region showed severe demyelination in both the spinal cord and cerebellar white matter in vivo [99,100] Later, it was confirmed that axonal PrPC and its α-cleavage are necessary for pro-myelination in the peripheral nervous system [101]. Using a co-isogenic PrP-knockout mice model, Kuffer et al. discovered that axonal PrPC promotes myelin maintenance in trans via binding to the adhesion G-protein-coupled receptor Adgrg6 on Schwann cells with an N-terminal flexible tail [7]. They also confirmed that mice lacking PrP developed chronic demyelinating neuropathy, which suggests that myelination homeostasis in the peripheral nervous system is a bona fide physiological function of PrPC [7]. Myelin maintenance was found to be regulated through the binding of an N-terminal released fragment of PrPC (presumably N1 or shed PrP) to Adgrg6 on Schwann cells.
The interaction activated Adgrg6, increased the cellular levels of cAMP and triggered a signaling cascade that promoted myelination [7]. The regulation of peripheral myelin maintenance by PrP^C was confirmed in five different PrP-knockout mouse model strains that developed late-onset peripheral neuropathy [101–103]. Recently, there was an attempt to develop a treatment for peripheral demyelinating diseases based on binding between the N-terminal domain of PrP^C and Adgrg6 [104]. In this study, they constructed an immunoadhesin molecule consisting of two flexible N-terminal domains of PrP^C linked to a crystallizable fragment (Fc) of immunoglobulin G1 (FT2Fc) [104]. The molecule showed favorable pharmacokinetic properties and showed potential in vitro but failed to have a therapeutic effect on the early molecular signs of demyelination in PrP-knockout mice [104].

PrP^C was also studied in connection to peripheral myelin development and regeneration after nerve injuries [105]. As PrP was found to be dispensable in this mechanism, it could be presumed that PrP has no major role in the peripheral nerve repair process or its absence might be compensated by other ligands [105].

Myelination and other physiological roles of PrP^C have been intensively studied on animal models with a knocked-out or knocked-down PrP gene expression. Studies have shown limited negative effects in mice [102,106–109], cattle [110] and goats [68,111,112] whereas studies on PrP-knockout mice or goats showed defects in the nervous system and sensitivity to oxidative stress [6,101,111,113]. Several PrP-knockout mice models were generated with a mixed background [106,109,114–116]. As the studies are not reproducible among models, this might raise the question of whether any observed phenotypes were actually due to polymorphisms in genes flanking Prnp or the result of PrP^C absence. To avoid this issue, it would be advisable to repeat key experiments using co-isogenic PrP-knockout mice.

Although the role of PrP^C in the CNS needs to be elucidated, PrP^C and PrP^C released fragments are indispensable in peripheral nerve myelin homeostasis but they may be dispensable in nerve recovery.

5. Prion Protein and Ischemic Strokes

In the previous section, we observed that knockout animals are more vulnerable to oxidative stress. Studies support the idea that PrP^C acts as an antioxidant by regulating glutathione reductase activity [117,118] and by regulating superoxide dismutase (SOD) through ion binding [119–123]. PrP-knockout mice showed a reduced protection against ROS whereas prion-infected mice showed increased levels of oxidative stress, most likely as a consequence of a PrP^C loss of function [124–126]. Under oxidative stress conditions, PrP mRNA levels increase, which implies that oxidative stress upregulates PrP^C expression [127]. Ischemic stroke is a condition where the loss of blood flow in a brain area causes hypoxic conditions and brain damage [128]. PrP-knockout animal models subject to ischemia showed intensive ischemic damage and a reduced chance of regeneration whereas the possibility of PrP^C synthesis resulted in PrP^C overexpression and decreased ischemic damage [127]. Studies on ischemic strokes have indicated that PrP^C overexpression can reduce the lesion size compared with wild-type mice, ascribing PrP^C a protective role in ischemia damage [129–135]. After an ischemic insult, PrP^C is associated with neuroprotective and regenerative processes by interacting with various cytosolic and transmembrane signal proteins. Among others, PrP^C has been associated with the upregulation of extracellular signal-regulated kinase (ERK1/2) [133,136,137], activation of the phosphatidylinositol 3-kinase/protein kinase B/Akt (PI3K/Akt) pathway [138–142], modulation of N-methyl-D-aspartate (NMDA) receptor-mediated toxicity [143], activation of the cAMP-dependent protein kinase A (PKA) pathway [144–146] and interaction with stress-inducible protein 1 (STI1) [146], all resulting in neuron survival, neurite outgrowth and neuroprotection.

PrP^C is a receptor of Fyn kinase, a member of the Src family of tyrosine kinases (SFKs) [146]. Through Fyn kinase activation, PrP^C mediates oligomer-induced toxicity in neurodegenerative diseases [147–150] and promotes neurite outgrowth by the phosphorylation of the GluN2A domain of the neuronal cell adhesion molecule (NCAM) [151]. Fyn
kinase and other members of the SFK family are involved in ischemic damage [152–155]. The inhibition of SFKs in a global ischemia model and the inhibition of the Fyn-mediated phosphorylation of GluN2A in a model of neonatal HII resulted in an increased neuronal survival [156–158] whereas the overexpression of Fyn in the model of neonatal HII led to increased brain damage [159]. The inhibition of SFKs in a mouse model of an ischemia also resulted in a decreased ischemic volume and improved cerebral function after provocation [155]. As this effect was not seen in Fyn-knockout mice, we suspect that ligands other than Fyn kinase may also affect ischemia insult recovery [155].

PrP\(_{\text{C}}\) fragments were also shown to be involved in ischemic stroke. Fragments N1 and N2 were shown to act protectively under cellular stress [160–162] and modulate the quiescence of neural stem cells in adult neurogenesis upon stroke [163] whereas PrP\(_{\text{C}}\) fragments C1 and C2 were involved in regulating p53-dependent apoptosis and cell survival [164]. Fragment C1 was found to be enriched in small EVs (sEVs) where it acted similarly to viral surface proteins [165,166]. Due to this, it may affect the intercellular information exchange between sEVs and their target cells as well as contributing to their uptake [63]. Brenna et al. studied the similarities between the cellular uptake of brain-derived sEVs from PrP-knockout mice and wild-type mice after a stroke [128]. They showed that sEVs lacking PrP were taken up significantly faster with a greater efficiency and were more easily sorted into lysosomes than sEVs containing PrP and fragment C1 [128]. Fragment N1 was also found to be involved in regulating the interactions between microglia and other brain cells. A recent in vitro study on a mixed neuronal lineage and microglia coculture system showed that fragment N1 stimulated a change in the cell morphology and metabolism and induced Cxcl10 secretion [167]. Furthermore, fragment N1 was shown to influence microglia to change the membrane composition to a higher GM1 content at the interaction sites with the surrounding cells in a co-culture yet only upon direct cell-to-cell contact [167]. Fragment N1 was also proposed to protect neurons against staurosporine-induced Caspase-3 activation in an ischemic model of the rat retina [60]. These results are supported by in vitro studies where the expression of PrP\(_{\text{C}}\) was protective against staurosporine or anisomycin-induced apoptosis [144,146]. Fragment N1 is also related to neuroprotection in neurodegenerative diseases, which is discussed in more detail in the next section. In the presence of anchored PrP\(_{\text{C}}\), recombinant PrP (recPrP) can induce ERK1/2 and Akt signaling on mesenchymal stem cells that may support neuronal differentiation [168], promote neurite outgrowth and facilitate axonal growth cone guidance [169]. Recently, it was reported that recPrP promotes neurite outgrowth and Schwann cell migration through the ERK1/2 pathway [170]. The activation involved NMDA receptors, low density lipoprotein receptor-related protein-1 (LRP1), SFKs and Trk receptors; it seemed to take place independently of anchored PrP\(_{\text{C}}\) [170]. In this mechanism, SFKs played a critical role in recPrP-initiated cell signaling by activating Trk receptors, which are upstream of ERK1/2 [170,171]. Although recPrP lacks glycosylation, it might be considered to be a suitable analog of shed PrP.

Prion protein and prion protein fragments are linked with intercellular communication and signaling, oxidative stress and neuroprotection and present an attractive target for the treatment and regulation of these mechanisms. Nevertheless, further studies should be conducted to confirm the effects of these molecules in the mentioned mechanisms.

6. Prion Protein and Neurodegeneration

Neurodegeneration is the progressive loss of the structure or function of neurons, which may ultimately involve cell death. On the molecular level, neurodegeneration is connected to accumulation of misfolded proteins. Accumulation of protein aggregates causes mitochondria dysfunction, induces oxidative stress and ultimately causes chronic inflammation. Neurodegeneration occurs in diseases such as prion disease, PD and AD due to the aggregation of PrP\(_{\text{Sc}}\) [26,172,173], \(\alpha\)-syn [174–177] and A\(\beta\) isoforms [178,179] and tau protein [180–183], respectively. Prion protein or prion protein fragments have been
found to interact with aggregating agents in different neurodegenerative diseases but their roles depend on the studied conditions [24,81,184,185].

It has been reported that PrP<sup>C</sup> binds a wide range of β-sheet-rich oligomers associated with neurodegenerative diseases [148–150]. PrP<sup>C</sup> engages metabotropic glutamate receptor 5 (mGluR5) and mediates oligomer-induced toxicity through Fyn kinase [175,186–188]. Activated Fyn kinase can phosphorylate the GluN2A and GluN2B subunits of NMDA receptors, which are then hyperactivated and cause calcium influx and cell death [20,189]. It has also been shown that PrP<sup>C</sup> can activate Fyn kinase-mediated Aβ oligomer toxicity by an interaction with LRP1 [190]. A recent study in this field suggested that, apart from LRP1, this process includes activated α2-macroglobulin and tissue-type plasminogen activator [191]. Studies have implied that binding between soluble protein aggregates and PrP<sup>C</sup> causes neurotoxicity and inhibits long-term potentiation (LTP) [30,192]. Opposing studies have also been published that report no significant effect of PrP<sup>C</sup> levels on Aβ-induced LTP in PrP-knockout mice [193], cell ablation or PrP overexpression [194]. The reasons for these discrepancies are unclear but they could be due to the use of different model systems and toxic or nontoxic species [195].

Aβ oligomers bind to PrP<sup>C</sup> at two binding sites within the flexible N-terminal part of PrP<sup>C</sup>, between amino acid residues 23–27 and 92–110 [192,195,196]. Apart from Aβ oligomers, PrP<sup>C</sup> has been reported to be a receptor for α-syn oligomers and tau aggregates. Similar to Aβ oligomers, anchored PrP<sup>C</sup> binds small soluble aggregates or shorter fibrils of α-syn oligomers or tau aggregates within the flexible N-terminal part [30,175,185,197–199]. PrP<sup>C</sup> has also been shown to uptake recombinant α-syn fibrils. A model system lacking PrP<sup>C</sup> showed a lower uptake of α-syn and α-syn fibrils in comparison with controls [177,185,197], resulting in less α-syn aggregation, astroglial activation and loss of dopaminergic neurons in the brains of PrP-knockout mice [185]. Furthermore, PrP-knockout mice did not exhibit α-syn-induced LTP impairment whereas treatment with an anti-PrP antibody prevented α-syn-induced LTP defects in a model of PD [175]. Although the mentioned studies support a PrP<sup>C</sup> and α-syn oligomer interplay, La Vitola et al. showed that PrP<sup>C</sup> was not mandatory for the mediation of α-syn oligomer detrimental effects in vitro or in vivo [33]. Although the discrepancy could not be explained in the study, it could also occur due to the use of a different protocol of soluble aggregate preparation or the use of different model systems. Anchored PrP<sup>C</sup> was also shown to bind tau aggregates and seemed to facilitate their uptake [30,198,200]. Absence of PrP<sup>C</sup> or pretreatment with anti-PrP blocking antibodies was shown to decrease the uptake of recombinant tau aggregates and abolish tau aggregate-induced toxicity [30,198,200].

Studies regarding recombinant PrP fragment N1 in neurodegenerative diseases have shown that these molecules can bind toxic Aβ oligomers at regions between amino acid residues 23–31 and 95–105. Fragment N1 neutralizes toxic Aβ oligomers by seizing them in the extracellular space and reduces oligomer-induced toxicity [61,195,201–204]. The protective effects of fragment N1 have also been observed in vivo in mice exposed to acute Aβ-induced toxicity [203]. Beland and coworkers observed increases in the α-cleavage of PrP<sup>C</sup> in the brains of AD patients [205]. As the N1 fragment abundantly binds Aβ oligomers, it may be indicated that the cleavage acts protectively in the development of diseases [205] whereas the inhibition of N1 production promotes AD progression [42].

PrP shedding reduces the level of cell-anchored PrP<sup>C</sup> [78]. This results in a decreased level of the substrate for prion replication and a decreased level of the receptor for toxic oligomers [85,206]. Similar to fragment N1, shed PrP is also believed to be protective in prion diseases and other neurodegenerative diseases [40,79,81]. As mentioned in the previous section, recPrP is similar to shed PrP. Although it lacks glycans, recPrP may be used as a model to predict the role of shed PrP in diseases. RecPrP was found to increase the development of synapses and neurite outgrowth in the presence of anchored PrP<sup>C</sup> [170,207]. Similar to fragment N1, recPrP also inhibited Aβ oligomer formation and neutralized Aβ oligomer toxicity in an AD model [208]. In vitro studies using recPrP and its derivatives showed that both the N-terminal and C-terminal domains of PrP are required for an efficient
inhibition of Aβ fibril elongation [202,208] and support the protective role of shed PrP in the inhibition of Aβ fibril formation. RecPrP was also shown to bind tau aggregates and α-syn oligomers and may neutralize their toxicity [30]. Although PrPSc shedding acts protectively, enhanced PrPSc shedding could lead to negative biological activity such as inflammation in the CNS [83,209]. Jarosz-Griffiths et al. [82] recently reported on the protective role of PrP shedding. The authors reported that siRNA-mediated ADAM10 knockdown reduced PrPSc shedding and increased Aβ oligomer binding whereas acitretin promoted PrPSc shedding and decreased Aβ oligomer binding in the neuroblastoma cells and in human-induced pluripotent stem cells [82].

In a recent paper by Linsenmeier et al., researchers evaluated the role of shed PrP in different models [81]. Using a polyclonal antibody sPrPG228 that specifically recognized murine PrP ending with G228 [210] they showed that in prion-diseased mice, shed PrP colocalized with PrPSc in amyloid plaques. Similar to the model of prion disease, shed PrP was also distributed to Aβ deposits in the brains of 5xFAD mice where it was found bound to Aβ oligomers and seen in the center of many amyloid plaques. Due to the knowledge in this field thus far, the authors proposed that physiologically shed PrP may act protectively in prion diseases and AD by blocking toxic oligomers and/or by precipitating them into less toxic deposits [81,211].

RecPrP and N1 may also inhibit Aβ oligomerization, neutralize cytotoxicity of preexisting Aβ oligomers, prevent the binding of oligomers with cell surface PrPSc and rescue the Aβ-induced impairment of LTP [212]. As recPrP and N1 both contain proposed binding sites of protein oligomers, both molecules were reported to also bind α-syn oligomers as well as mediate the co-clustering of α-syn oligomers and AD-associated amyloid-β oligomers [199].

PrPSc is enriched in extracellular vesicles (EVs) [128,213,214]. Little is known regarding the physiological functions of PrPSc in EVs. Several studies have suggested that PrPSc in EVs protect cells against Aβ toxicity [214–217]. The mechanism behind the neutralization of toxic Aβ oligomers by EVs is not known; nevertheless, it is presumed that it is similar to the recPrP or N1-mediated process. It has been proposed that exosomal PrPSc catches Aβ oligomers at the N-terminal PrP region (amino acid residues 23–31 and 95–105) [203], neutralizes the oligomers, promotes the formation of Aβ fibrils and upregulates internalization and degradation of the aggregates by microglia [214–217]. As recPrP and anchored PrPSc have been shown to bind tau and α-syn oligomers [30], exosomal PrPs are expected to act in the same manner. By binding free toxic tau or α-syn oligomers in the extracellular space, exosomal PrPs prevent toxic oligomer binding to anchored PrPSc and inhibit toxic signaling in the CNS of patients with diseases. Exosomes associated with PrPSc have been shown to be infectious and pose a danger of spreading prion disease [218–222]. Although there is no direct study yet, exosomal PrPSc might also induce CNS inflammation. More work needs to be undertaken to examine other biological activities that exosomal PrPSc may possess.

On the basis of the determined oligomer binding domains, researchers have designed potential treatment strategies for AD based on synthetic peptides [204,223] and functional Aβ oligomer-binding compounds [149]. The designed synthetic peptides have been shown to reduce the initial rate of Aβ fibrillization, inhibit the aggregation pathway of Aβ by reducing Aβ oligomer uptake and protect cultured hippocampal neurons from the oligomer-induced retraction of neurites and loss of cell membrane integrity [204] whereas D-peptide RD2D3 has been shown to be successful in interfering with the PrPSc–Aβ oligomer assembly and has been proposed as a promising therapeutic agent in AD [223].

7. Conclusions

The reviewed studies support the fact that prion protein and/or prion protein fragments are involved in myelin homeostasis, ischemia and neurodegeneration where they may take on different roles (Figure 2). According to the current information, anchored PrP and/or released fragments (N1, shed PrP) interact with Adgrg6 to regulate peripheral nerve myelin homeostasis. Although there have been attempts to connect PrP to other
Adgrg6-mediated processes, no direct involvement has been perceived. In strokes, the expression of PrP is upregulated. Anchored PrP takes part in mediating signaling pathways through transmembrane and cytosolic receptor proteins. Although further study is needed, the released forms may play decisive roles in neuroprotection and regeneration, including the regulation of interactions between microglia and brain cells and the promotion of neurogenesis. EVs and sEVs highly enriched in PrP fragments may be important delivery mechanisms in neuroprotection and neurodegeneration; further studies are needed to prove their roles. In neurodegenerative diseases, anchored PrP acts as a receptor for Aβ oligomers, α-syn oligomers and tau aggregates and may mediate oligomer-induced cytotoxicity. The point of interaction between the oligomer and PrP may be an attractive site for drug development but therapy may also include the regulation of other partners involved in this process. Arguing their protective role, released PrP fragments may bind toxic oligomers and enable their depletion. Supporting this role, shed PrP has been shown to bind PrPSc and Aβ oligomers in amyloid plaques, which may be less toxic than oligomers. To conclude, there are many indications suggesting that prion protein and prion protein fragments may have multiple (sometimes even intertwined) roles in strokes and neurodegeneration. To undoubtedly elucidate their role(s) in these processes, further studies are needed in these fields.

Figure 2. Proteins, signaling pathways and interactions that may be affected by PrP and/or PrP fragments. This scheme presents various proteins, signaling pathways and interactions that reportedly involve PrP and/or its fragments. In ischemic stroke, PrP species were found to be involved in modulating neuroprotection, neurite outgrowth, neurogenesis and angiogenesis. In neurodegenerative diseases, released PrP fragments may act protectively whereas anchored PrP regulates oligomer-induced toxicity. PrP and its derivatives are also involved in Adgrg6-induced myelination homeostasis (orange) and may be involved in microglia communication and differentiation as well as regulating intercellular communication through EVs and sEVs, etc. Several of the proposed interplays are regulated by a direct interaction with PrP species whereas others are regulated indirectly. Protective pathways and interactions are colored blue whereas green color presents harmful outcomes.
Author Contributions: V.K. conceptualized the manuscript scope and wrote the first draft; V.Č.Š. conceptualized the manuscript scope and critically reviewed the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: The work was funded by Slovenian Research Agency (ARRS grant number P4-0176).

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Scheckel, C.; Aguzzi, A. Prions, prionoids and protein misfolding disorders. Nat. Rev. Genet. 2018, 19, 405–418. [CrossRef] [PubMed]
2. O’Carroll, A.; Coyle, J.; Gambin, Y. Prions and Prion-like assemblies in neurodegeneration and immunity: The emergence of universal mechanisms across health and disease. Semin. Cell Dev. Biol. 2020, 99, 115–130. [CrossRef] [PubMed]
3. Ritchie, D.L.; Barria, M.A. Prion Diseases: A Unique Transmissible Agent or a Model for Neurodegenerative Diseases? Biomolecules 2021, 11, 207. [CrossRef] [PubMed]
4. Herms, J.; Tings, T.; Gall, S.; Madlung, A.; Giere, A.; Siebert, H.; Schurmann, P.; Windl, O.; Broux, N.; Kretzschmar, H. Evidence of presynaptic location and function of the prion protein. Neurosci. 1999, 19, 8866–8875. [CrossRef]
5. Bendheim, P.E.; Brown, H.R.; Rudelli, R.D.; Scala, L.J.; Golla, N.L.; Wen, G.Y. Nearly ubiquitous tissue distribution of the scrapie agent prion protein precursor. Neurology 1992, 42, 149. [CrossRef]
6. Wulf, M.-A.; Senatore, A.; Aguzzi, A. The biological function of the cellular prion protein: An update. BMC Biol. 2017, 15, 34. [CrossRef]
7. Carulla, P.; Bribián, A.; Rangel, A.; Gavín, R.; Ferrer, I.; Caelles, C. Neuroprotective role of PrPC against kainate-induced epileptic seizures and cell death depends on the modulation of JNK3 activation by GluR6−/−PSD-95 binding. Mol. Biol. Cell 2011, 22, 3041–3054. [CrossRef]
8. Carulla, P.; Llorens, F.; Matamoros-Angles, A.; Aguilar-Calvo, P.; Espinosa, J.C.; Gavín, R. Involvement of PrPC in kainate-induced excitotoxicity in several mouse strains. Sci. Rep. 2015, 5, 11971. [CrossRef]
9. Harris, D.A. Cellular biology of prion diseases. J. Biol. Chem. 1999, 274, 115–130. [CrossRef] [PubMed]
10. O’Carroll, A.; Coyle, J.; Gambin, Y. Prions and Prion-like assemblies in neurodegeneration and immunity: The emergence of universal mechanisms across health and disease. Semin. Cell Dev. Biol. 2020, 99, 115–130. [CrossRef] [PubMed]
11. Harris, D.A. Cellular biology of prion diseases. J. Biol. Chem. 1999, 274, 115–130. [CrossRef] [PubMed]
12. Carulla, P.; Llorens, F.; Matamoros-Angles, A.; Aguilar-Calvo, P.; Espinosa, J.C.; Gavín, R. Prion protein and copper cooperatively protect neurons by modulating antioxidative capacity. Mol. Biol. Cell 2011, 22, 3041–3054. [CrossRef] [PubMed]
13. Cingaram, P.K.R.; Nyeste, A.; Dondapati, D.T.; Fodor, E.; Welker, E. Prion Protein Does Not Confer Resistance to Hippocampus-Derived ZPl Cells Against the Toxic Effects of CuZn2+, Mn2+, Zn2+ and Co2+ Not Supporting a General Protective Role for PrP in Transition Metal Induced Toxicity. PLoS ONE 2015, 10, e0139219. [CrossRef] [PubMed]
14. Moya, K.L.; Hässig, R.; Créminon, C.; Lafont, I.; Giambardino, L. Enhanced detection and retrograde axonal transport of PrPc in peripheral nerve: Cellular prion protein in peripheral nerve. J. Neurochem. 2003, 88, 155–160. [CrossRef]
15. Haeberle, A.M.; Ribaut-Barassin, C.; Bombarde, G.; Mariani, J.; Hunsmann, G.; Grassi, J. Synaptic prion protein immuno-reactivity in the rodent cerebellum. Microsc. Res. Tech. 2000, 50, 56–66. [CrossRef]
16. Baixeras, E.; Martin, A.; Ripoll, X.; Covarrubias, M.; Alberti, P.; Millan, J.; Lezcano, L.; Marin, S. Localization of the prion protein in the central nervous system. J. Neurosci. 2000, 20, 1343–1349. [CrossRef]
17. Moya, K.L.; Hässig, R.; Créminon, C.; Lafont, I.; Giambardino, L. Enhanced detection and retrograde axonal transport of PrPc in peripheral nerve: Cellular prion protein in peripheral nerve. J. Neurochem. 2003, 88, 155–160. [CrossRef]
18. Haeberle, A.M.; Ribaut-Barassin, C.; Bombarde, G.; Mariani, J.; Hunsmann, G.; Grassi, J. Synaptic prion protein immuno-reactivity in the rodent cerebellum. Microsc. Res. Tech. 2000, 50, 56–66. [CrossRef]
19. Moya, K.L.; Hässig, R.; Créminon, C.; Lafont, I.; Giambardino, L. Enhanced detection and retrograde axonal transport of PrPc in peripheral nerve: Cellular prion protein in peripheral nerve. J. Neurochem. 2003, 88, 155–160. [CrossRef]
20. Haeberle, A.M.; Ribaut-Barassin, C.; Bombarde, G.; Mariani, J.; Hunsmann, G.; Grassi, J. Synaptic prion protein immuno-reactivity in the rodent cerebellum. Microsc. Res. Tech. 2000, 50, 56–66. [CrossRef]
21. Baixeras, E.; Martin, A.; Ripoll, X.; Covarrubias, M.; Alberti, P.; Millan, J.; Lezcano, L.; Marin, S. Localization of the prion protein in the central nervous system. J. Neurosci. 2000, 20, 1343–1349. [CrossRef] [PubMed]
22. Prusiner, S.B. Prions. Proc. Natl. Acad. Sci. USA 1998, 95, 13363–13383. [CrossRef] [PubMed]
23. Zahn, R.; Liu, A.; Luhrs, T.; Riek, R.; von Schroetter, C.; Lopez Garcia, F.; Billette, M.; Calzolai, L.; Wider, G.; Wuthrich, K. NMR solution structure of the human prion protein. Proc. Natl. Acad. Sci. USA 2000, 97, 145–150. [CrossRef] [PubMed]
24. Dexter, E.; Kong, Q. Neuroprotective effect and potential of cellular prion protein and its cleavage products for treatment of neurodegenerative disorders part I. A literature review. Expert Rev. Neurother. 2021, 21, 969–982. [CrossRef]
25. Castle, A.R.; Gill, A.C. Physiological Functions of the Cellular Prion Protein. Front. Mol. Biosci. 2017, 4, 19. [CrossRef]
26. Pan, K.M.; Baldwin, M.; Nguyen, J.; Gasset, M.; Serban, A.; Groth, D.; Mehlhorn, I.; Huang, Z.W.; Fletterick, R.J.; Cohen, F.E.; et al. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. *Proc. Natl. Acad. Sci. USA* 1995, 90, 10962–10966. [CrossRef]

27. Walker, L.C.; Jucker, M. Neurodegenerative diseases: Expanding the prion concept. *Annu. Rev. Neurosci.* 2015, 38, 87–103. [CrossRef]

28. Amin, L.; Harris, D.A. \( \alpha \beta \) receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. *Nat. Commun.* 2021, 12, 3451. [CrossRef]

29. Castillo-Carranza, D.L.; Gerson, J.E.; Sengupta, U.; Guerrero-Muñoz, M.J.; Lasagna-Reeves, C.A.; Kayed, R. Specific targeting of tau oligomers in 

30. Borchelt, D.R.; Rogers, M.; Stahl, N.; Telling, G.; Prusiner, S.B. Release of the cellular prion protein from cultured cells after loss of

31. La Vitola, P.; Beeg, M.; Balducci, C.; Santamaria, G.; Restelli, E.; Colombo, L.; Caldinelli, L.; Pollegioni, L.; Gobbi, M.; Chiesa, R.; Pietri, M.; Baudry, A.; Dakowski, C.; Tixador, P.; Ardila-Osorio, H.; Haeberl 

32. Oliveira-Martins, J.B.; Yusa, S.-I.; Calella, A.M.; Bridel, C.; Baumann, F.; Dametto, P.; Aguzzi, A. Unexpected Tolerance of

33. Liang, J.; Wang, W.; Colom-Cadena, M.; Rose, J.; Liao, M.; Asfaw, A.; Hall, T.C.; Ding, L.; DeSousa, A.; et al. PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins. *Acta Neuropathol.* 2020, 139, 503–526. [CrossRef]

34. Stahl, N.; Borchelt, D.R.; Prusiner, S.B. Differential release of cellular and scrapie prion proteins from cellular membranes by phosphatidylinositol-specific phospholipase C. *Biochemistry* 1993, 29, 5405–5412. [CrossRef]

35. Borchelt, D.R.; Rogers, M.; Stahl, N.; Telling, G.; Prusiner, S.B. Release of the cellular prion protein from cultured cells after loss of its glycosylated phospholipid anchor. *Glycobiology* 1993, 3, 319–329. [CrossRef]

36. Chen, S.G.; Teplow, D.B.; Parchi, P.; Teller, J.K.; Gambetti, P.; Autilio-Gambetti, L. Truncated forms of the human prion protein in

37. Mange, A.; Beranger, F.; Pech, K.; Onodera, T.; Frobert, Y.; Lehmann, S. Alpha- and beta-cleavages of the amino-terminus of the cellular prion protein. *Biol. Cell* 2004, 96, 125–132. [CrossRef]

38. Oliveira-Martins, J.B.; Yusa, S.-I.; Calella, A.M.; Bridel, C.; Baumann, F.; Dametto, P.; Aguzzi, A. Unexpected Tolerance of \( \alpha \)-Cleavage of the Prion Protein to Sequence Variations. *PLoS ONE* 2010, 5, e9107. [CrossRef]

39. Harris, D.A.; Huber, M.T.; Dijken, P.; Shyng, S.L.; Chait, B.T.; Wang, R. Processing of a cellular prion protein: Identification of N-and C-terminal cleavage sites. *Biochemistry* 1993, 32, 1009–1016. [CrossRef]

40. Linsenmeier, L.; Almeppen, H.C.; Wetzel, S.; Mohammadi, B.; Saftig, P.; Glatzel, M. Diverse functions of the prion protein—Does proteolytic processing hold the key? *Biochim. Biophys. Acta* 2017, 1864, 2128–2137. [CrossRef]

41. Laffont-Proust, I.; Fauchex, B.A.; Hässig, R.; Szadovitch, V.; Simon, S.; Grassi, J.; Hauw, J.-J.; Moya, K.L.; Haïk, S. The N-terminal cleavage of cellular prion protein in the human brain. *FEBS Lett.* 2005, 579, 6333–6337. [CrossRef]

42. Pietri, M.; Dakowski, C.; Hannouli, S.; Alleaume-Butaux, A.; Fernandez-Rapp, J.; Ragagnin, A.; Mouillet-Richard, S.; Haïk, S.; Bailly, Y.; Peyrin, J.-M.; et al. PDK1 decreases TACE-mediated \( \alpha \)-secretase activity and promotes disease progression in prion and Alzheimer’s diseases. *Nat. Med.* 2013, 19, 1124–1131. [CrossRef] [PubMed]

43. Alleaume-Butaux, A.; Nicot, S.; Pietri, M.; Baudry, A.; Dakowski, C.; Tixador, P.; Ardila-Osorio, H.; Haebeler, A.-M.; Bailly, Y.; Peyrin, J.-M.; et al. Double-Edge Sword of Sustained ROCK Activation in Prion Diseases through Neuritogenesis Defects and Prion Accumulation. *PLoS Pathog.* 2011, 5, e1005073. [CrossRef] [PubMed]

44. Vincent, B.; Palet, E.; Frobert, Y.; Lehmann, S.; Grassi, J.; Checher, F. Phorbol ester-regulated cleavage of normal prion protein in HEK293 human cells and murine neurons. *J. Biol. Chem.* 2000, 275, 35612–35616. [CrossRef] [PubMed]

45. Vincent, B.; Palet, E.; Saftig, P.; Frobert, Y.; Hartmann, D.; De Strooper, B.; Grassi, J.; Lopez-Perez, E.; Checher, F. The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein. *J. Biol. Chem.* 2001, 276, 37743–37746. [CrossRef]

46. Liang, J.; Wang, W.; Sorensen, D.; Medina, S.; Ichenko, S.; Kiselar, J.; Surewicz, W.K.; Booth, S.A.; Kong, Q. Cellular Prion Protein Regulates Its Own \( \alpha \)-Cleavage through ADAM8 in Skeletal Muscle. *J. Biol. Chem.* 2012, 287, 16510–16520. [CrossRef]

47. McDonald, A.J.; Dibble, J.P.; Evans, E.G.B.; Millhauser, G.L. A New Paradigm for Enzymatic Control of \( \alpha \)-Cleavage and \( \beta \)-Cleavage of the Prion Protein. *J. Biol. Chem.* 2014, 289, 803–813. [CrossRef]

48. Jimenez-Huete, A.; Lievens, P.M.; Vidal, R.; Piccardo, P.; Ghetti, B.; Tagliavini, F.; Francione, B.; Pelli, F. Endogenous proteolytic cleavage of normal and disease-associated isoforms of the human prion protein in neural and non-neural tissues. *Am. J. Pathol.* 1998, 153, 1561–1572. [CrossRef]

49. Kuczius, T.; Grassi, J.; Karch, H.; Grochup, M.H. Binding of N- and C-terminal anti-prion protein antibodies generates distinct phenotypes of cellular prion proteins (PrPC) obtained from human, sheep, cattle and mouse. *FEBS J.* 2007, 274, 1492–1502. [CrossRef]

50. Shyng, S.L.; Huber, M.T.; Harris, D.A. A prion protein cycles between the cell surface and an endocytic compartment in cultured neuroblastoma cells. *J. Biol. Chem.* 1993, 268, 15922–15928. [CrossRef]
51. Taraboulos, A.; Scott, M.; Semenov, A.; Avrahami, D.; Laszlo, L.; Prusiner, S.B. Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. *J. Cell Biol.* 1995, 129, 121–132. [CrossRef] [PubMed]

52. Zhao, H.; Klingeborn, M.; Simonsson, M.; Linne, T. Proteolytic cleavage and shedding of the bovine prion protein in two cell culture systems. *Viruses* 2006, 11, 49–55. [CrossRef] [PubMed]

53. Walmsley, A.R.; Watt, N.T.; Taylor, D.R.; Perera, W.S.S.; Hooper, N.M. α-cleavage of the prion protein occurs in a late compartment of the secretory pathway and is independent of lipid rafts. *Mol. Cell Neurosci.* 2009, 40, 242–248. [CrossRef] [PubMed]

54. Nunziante, M.; Gilch, S.; Schatzl, H.M. Essential Role of the Prion Protein N Terminus in Subcellular Trafficking and Half-life of Cellular Prion Protein. *J. Biol. Chem.* 2003, 278, 3726–3734. [CrossRef]

55. Béland, M.; Roucou, X. The prion protein unstructured N-terminal region is a broad-spectrum molecular sensor with diverse and contrasting potential functions. *J. Neurochem.* 2012, 120, 853–868. [CrossRef]

56. Nieznanski, K.; Rutkowski, M.; Dominik, M.; Stepkowski, D. Proteolytic processing and glycosylation influence formation of porcine prion protein complexes. *Biochem. J.* 2005, 387, 93–100. [CrossRef]

57. Wik, L.; Klingeborn, M.; Willander, H.; Linne, T. Separate mechanisms act concurrently to shed and release the prion protein from the cell. *Prion* 2012, 6, 498–509. [CrossRef]

58. Lewis, V.; Hill, A.F.; Haigh, C.L.; Klug, G.M.; Watson, V.A.; Collins, S.J. Increased proportions of C1 truncated prion protein protect against cellular M1000 prion infection. *J. Neuropathol. Exp. Neurol.* 2009, 68, 1125–1135. [CrossRef]

59. Westergard, L.; Turnbaugh, J.A.; Harris, D.A. A naturally occurring C-terminal fragment of the prion protein (PrP) delays disease and acts as a dominant-negative inhibitor of PrPSc formation. *J. Biol. Chem.* 2011, 286, 44234–44242. [CrossRef]

60. Guillot-Sestier, M.V.; Sunyach, C.; Druon, C.; Scarzello, S.; Checler, F. The alpha-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo. *J. Biol. Chem.* 2009, 284, 35973–35986. [CrossRef]

61. Pushie, M.J.; Vogel, H.J. Modeling by Assembly and Molecular Dynamics Simulations of the Low Cu2+ Occupancy Form of the Mammalian Prion Protein Octarepeat Region: Gaining Insight into Cu2+-Mediated Enzyme Resistance through Cu2+-Binding. *Biophys. J.* 2012, 103, 304–315. [CrossRef] [PubMed]

62. Yusa, S.; Oliveira-Martins, J.B.; Sugita-Konishi, Y.; Kikuchi, Y. Cellular prion protein: From physiology to pathology. *Viruses* 2012, 4, 3109–3131. [CrossRef] [PubMed]

63. Altmann, H.C.; Puig, B.; Dobler, F.; Thurm, D.K.; Faller, C.; Krasemann, S.; Glatzel, M. Proteolytic processing of the prion protein in health and disease. *Am. J. Neurodegener. Dis.* 2012, 1, 15–31. [PubMed]

64. McMahon, H.E.M.; Mang, G.M.; Masters, C.L.; Lawson, V.A.; Collins, S.J. Proteolytic processing and glycosylation influence formation of porcine prion protein complexes. *Biochem. J.* 2003, 378, 1–12. [CrossRef] [PubMed]

65. Altmeppen, H.C.; Puig, B.; Dohler, F.; Thurm, D.K.; Falker, C.; Krasemann, S.; Glatzel, M. Proteolytic processing of the prion protein protect against cellular M1000 prion infection. *J. Neuropathol. Exp. Neurol.* 2009, 68, 1125–1135. [CrossRef]

66. Engelke, A.D.; Gonsberg, A.; Thapa, S.; Jung, S.; Laszlo, M.; Roucou, X. The prion protein unstructured N-terminal region is a broad-spectrum molecular sensor with diverse and contrasting potential functions. *J. Neurochem.* 2012, 120, 853–868. [CrossRef]

67. Engelke, A.D.; Gonsberg, A.; Thapa, S.; Jung, S.; Ulbrich, S.; Seidel, R.; Basu, S.; Mullhaup, G.; Baier, M.; Engelhard, M.; et al. Dimerization of the cellular prion protein inhibits propagation of scrapie prions. *J. Biol. Chem.* 2018, 293, 8020–8031. [CrossRef] [PubMed]

68. Neumann, A.; Prinz, M.; Maissen, M.; Rülicke, T.; Raeber, A.J.; Aguzzi, A. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease. *Cell* 2003, 113, 49–60. [CrossRef]

69. Meier, P.; Genoud, N.; Prinz, M.; Maissen, M.; Rülicke, T.; Raeber, A.J.; Aguzzi, A. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease. *Cell* 2003, 113, 49–60. [CrossRef]

70. Parizek, P. Similar turnover and shedding of the cellular prion protein in primary lymphoid and neuronal cells. *J. Biol. Chem.* 2001, 276, 44627–44632. [CrossRef]

71. Oesch, B.; Westaway, D.; Walchli, M.; McKinley, M.P.; Kent, S.B.; Aebbersold, R.; Barry, R.A.; Tempst, P.; Teplow, D.B.; Hood, L.E.; et al. A cellular gene encodes scrapie PrP-27-30 protein. *Cell* 1985, 40, 735–746. [CrossRef]

72. Rogers, M.; Yehiely, F.; Scott, M.; Prusiner, S.B. Conversion of truncated and elongated prion proteins into the scrapie isoform in cultured cells. *Proc. Natl. Acad. Sci. USA* 1993, 90, 3182–3186. [CrossRef] [PubMed]

73. Lewis, V.; Johanssen, V.A.; Crouch, P.J.; Klug, G.M.; Hooper, N.M.; Collins, S.J. Prion protein “γ-cleavage”: Characterizing a novel endoproteolytic processing event. *Cell Mol. Life Sci.* 2016, 73, 667–683. [CrossRef] [PubMed]

74. Haigh, C.; Collins, S. Endoproteolytic cleavage as a molecular switch regulating and diversifying prion protein function. *Neural Regen. Res.* 2016, 11, 238–239. [CrossRef] [PubMed]

75. Kojima, A.; Konishi, M.; Akizawa, T. Prion Fragment Peptides Are Digested with Membrane Type Matrix Metalloproteinases and Acquire Enzyme Resistance through Cu2+-Binding. *Biomolecules* 2014, 4, 510–526. [CrossRef]

76. Stahl, N.; Baldwin, M.A.; Burlingame, A.L.; Prusiner, S.B. Identification of glycosinositol phospholipid linked and truncated forms of the scrapie prion protein. *Biochemistry* 1990, 29, 8879–8884. [CrossRef]

77. Tagliavini, F.; Prelli, F.; Porro, M.; Salmona, M.; Bugiani, O.; Frangione, B. A soluble form of prion protein in human cerebrospinal fluid: Implications for prion-related encephalopathies. *Biomed. Biophys. Res. Commun.* 1992, 184, 1398–1404. [CrossRef]

78. Altmeppen, H.C.; Prox, J.; Krasemann, S.; Puig, B.; Kruiszewski, K.; Dobler, F.; Bernreuther, C.; Hoaxha, A.; Linsenmeier, L.; Sikorska, B.; et al. The sheddase ADAM10 is a potent modulator of prion disease. *Elife* 2015, 4, e04260. [CrossRef]
Glatzel, M.; Linsenmeier, L.; Kohlmann, S.; Puig, B.; Altmann, H.C. Shedding light on prion disease. *Prion* 2015, 9, 244–256. [CrossRef]

Altmann, H.C.; Prox, J.; Puig, B.; Kohlmann, S.; Faller, C.; Krasemann, S.; Glatzel, M. Roles of endoproteolytic α-cleavage and shedding of the prion protein in neurodegeneration. *FEBS J.* 2013, 280, 4338–4347. [CrossRef]

Linsenmeier, L.; Mohammad, B.; Shafiq, M.; Frontzek, K.; Bär, J.; Shrivastava, A.N.; Damme, M.; Song, F.; Schwarz, A.; Da Vela, S.; et al. Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies. *Sci. Adv.* 2021, 7, eabj1826. [CrossRef] [PubMed]

Jarosz-Griffiths, H.H.; Corbett, N.J.; Rowland, H.A.; Fisher, K.; Jones, A.C.; Baron, J.; Howell, G.J.; Cowley, S.A.; Chintawar, S.; Cader, M.Z.; et al. Proteolytic shedding of the prion protein via activation of metalloproteinase ADAM10 reduces cellular binding and toxicity of amyloid-β oligomers. *J. Biol. Chem.* 2019, 294, 7085–7097. [CrossRef] [PubMed]

Megra, B.W.; Eugenin, E.A.; Berman, J.W. The Role of Shed PrP(C) in the Neuropathogenesis of HIV Infection. *J. Immunol.* 2017, 199, 224–232. [CrossRef] [PubMed]

Taylor, D.R.; Parkin, E.T.; Cocklin, S.L.; Ault, J.R.; Ashcroft, A.E.; Turner, A.J. Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein. *J. Biol. Chem.* 2009, 284, 22590–22600. [CrossRef] [PubMed]

Dvorakova, E.; Vranac, T.; Janouskova, O.; Černilec, M.; Koren, S.; Lukan, A.; Novakova, J.; Matej, R.; Holada, K.; Čurin Šerbec, V. Detection of the GPI-anchorless prion protein fragment PrP226* in human brain. *BMC Neuro.* 2013, 13, 126. [CrossRef] [PubMed]

Kovač, V.; Černilec, M.; Vranac, T.; Popović, M.; Hafner, I.; Jeral, R. Monoclonal antibody against a peptide of human prion protein discriminates between Creutzfeldt-Jacob's disease-affected and normal brain tissue. *J. Biol. Chem.* 2004, 279, 3694–3698. [CrossRef]

Kovač, V.; Zupaničič, B.; Ic, G.; Plavec, J.; Vranac, T.; Čurin Šerbec, V. Antibody variable-region sequencing as a method for hybridoma cell-line authentication. *Appl. Microbiol. Biotechnol.* 2016, 871, 1071–1078. [CrossRef] [PubMed]

Kovač, V.; Hafner-Bratković, I.; Čurin Šerbec, V. Prion Proteins Without the Glycophosphatidylinositol Anchor: Potential Biomarkers in Neurodegenerative Diseases. *Biomark. Insights* 2018, 13, 203–209. [CrossRef] [PubMed]

Kovač, V.; Čurin Šerbec, V. Prion Proteins Without the Glycophosphatidylinositol Anchor: Potential Biomarkers in Neurodegenerative Diseases. *Biomark. Insights* 2018, 13, 203–209. [CrossRef] [PubMed]

Kovač, V.; Čurin Šerbec, V.; Hafner, I. PrP overdrive: Does inhibition of α-cleavage contribute to PrP(C) toxicity and prion disease? *Prion* 2014, 8, 183–191. [CrossRef] [PubMed]

Tucher, J.; Linke, D.; Koudelka, T.; Cassidy, L.; Tredup, C.; Wichert, R.; Pietrzik, C.; Tholey, A. LC-MS-based cleavage site profiling of the proteases ADAM10 and ADAM17 using proteome-deromed peptide libraries. *J. Proteome Res.* 2014, 13, 2205–2214. [CrossRef] [PubMed]

Jansen, C.; Parchi, P.; Capellari, S.; Vermeij, A.J.; Corrado, P.; Baas, F.; Strammiello, R.; van Gool, W.A.; van Swieten, J.C.; Rozemuller, A.J. Prion protein amyloidosis with divergent phenotype associated with two novel nonsense mutations in PRNP. *Acta Neuropathol.* 2010, 119, 189–197. [CrossRef] [PubMed]

Čurin Šerbec, V.; Bresjanac, M.; Popović, M.; Pretnar Hartman, K.; Galvani, V.; Rupreht, R.; Černilec, M.; Vranac, T.; Hafner, I. Lethal recessive myelin toxicity of prion protein lacking its central domain. *EMBO J.* 2003, 224–232. [CrossRef] [PubMed]

Radovanovic, I. Truncated prion protein and Doppel are myelinotoxic in the absence of oligodendrocytic PrPC. *J. Neurosci.* 2005, 25, 4879–4888. [CrossRef]
104. Henzi, A.; Senatore, A.; Lakkaraju, A.K.K.; Scheckel, C.; Mühle, J.; Reimann, R.; Sorge, S.; Schertler, G.; Toyka, K.V.; Aguzzi, A. Soluble dimeric prion protein ligand activates Adgrg6 receptor but does not rescue early signs of demyelination in PrP-deficient mice. *PLoS ONE* 2020, 15, e0242137. [CrossRef]

105. Henzi, A.; Aguzzi, A. The prion protein is not required for peripheral nerve de- and remyelination after crush injury. *PLoS ONE* 2021, 16, e0245944. [CrossRef]

106. Büeler, H.; Fischer, M.; Lang, Y.; Bluthmann, H.; Lipp, H.P.; DeArmond, S.J.; Prusiner, S.B.; Aguet, M.; Weissmann, C. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. *Nature* 1992, 356, 577–582. [CrossRef]

107. Manson, J.C.; Clarke, A.R.; Hooper, M.L.; Aitchison, L.; McConnell, I.; Hope, J. 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. *Mol. Neurobiol.* 1994, 8, 121–127. [CrossRef]

108. Steele, A.D.; Lindquist, S.; Aguzzi, A. The prion protein knockout mouse: A phenotype under challenge. *Prion* 2007, 1, 83–93. [CrossRef]

109. Rossi, D.; Cazzolli, A.; Flechsig, E.; Klein, M.A.; Rülicke, T.; Aguzzi, A.; Weissmann, C. Onset of ataxia and Purkinje cell loss in PrP null mice inversely correlated with Dpl level in brain. *EMBO J.* 2001, 20, 694–702. [CrossRef]

110. Richt, J.A.; Kasinathan, P.; Hamir, A.N.; Castilla, J.; Sathiyaseelan, T.; Vargas, F. Production of cattle lacking prion protein. *Biotechnol.* 2007, 25, 132–138. [CrossRef]

111. Skedsmo, F.S.; Malachin, G.; Våge, D.I.; Hammervold, M.M.; Salvesen, Ø.; Ersdal, C.; Ranheim, B.; Stafsnes, M.H.; Bartosova, Z.; Bruehim, P.; et al. Demyelinating polyneuropathy in goats lacking prion protein. *FASEB J.* 2020, 34, 2359–2375. [CrossRef] [PubMed]

112. Skedsmo, F.S.; Malachin, G.; Våge, D.I.; Hammervold, M.M.; Salvesen, Ø.; Ersdal, C.; Ranheim, B.; Stafsnes, M.H.; Bartosova, Z.; Bruehim, P.; et al. Demyelinating polyneuropathy in goats lacking prion protein. *FASEB J.* 2020, 34, 2359–2375. [CrossRef] [PubMed]

113. Richt, J.A.; Kasinathan, P.; Hamir, A.N.; Castilla, J.; Sathiyaseelan, T.; Vargas, F. Production of cattle lacking prion protein. *Biotechnol.* 2007, 25, 132–138. [CrossRef]

114. Sakaguchi, S.; Katamine, S.; Nishida, N.; Moriuchi, R.; Shigematsu, K.; Sugimoto, T.; Nakatani, A.; Kataoka, Y.; Houtani, T.; Shirabe, S.; et al. Loss of cerebellar Purkinje cells in aged mice homozygous for a disrupted PrP gene. *Nature* 1996, 380, 528–531. [CrossRef] [PubMed]

115. Moore, R.C.; Lee, I.Y.; Silverman, G.L.; Harrison, P.M.; Strome, R.; Heinrich, C.; Karunaratne, A.; Pasternak, S.H.; Chishti, M.A.; Liang, Y.; et al. Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppel. *J. Mol. Biol.* 1999, 292, 797–817. [CrossRef] [PubMed]

116. Mallucci, G.R.; Ratté, S.; Asante, E.A.; Linehan, J.; Gowland, I.; Jefferys, J.G.; Collinge, J. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. *Embo J.* 2002, 21, 202–210. [CrossRef]

117. White, A.R.; Collins, S.J.; Mahler, F.; Jobling, M.F.; Stewart, L.R.; Thyer, J.M. Prion protein-deficient neurons reveal lower glutathione reductase activity and increased susceptibility to hydrogen peroxide toxicity. *Am. J. Pathol.* 1999, 155, 1723–1730. [CrossRef]

118. Hutter, G.; Heppner, F.L.; Aguzzi, A. No Superoxide Dismutase Activity of Cellular Prion Protein in vivo. *Biol. Chem.* 2003, 384, 1279–1285. [CrossRef]

119. Davies, P.; Brown, D.R. The chemistry of copper binding to PrP: Is there sufficient evidence to elucidate a role for copper in protein function? *Biochem. J.* 2008, 410, 237–244. [CrossRef]

120. Brown, D.R.; Nicholas, R.S.; Canevari, L. Lack of prion protein expression results in a neuronal phenotype sensitive to stress. *J. Neurosci. Res.* 2002, 67, 211–224. [CrossRef]

121. Brown, D.R.; Boon-Seng, W.; Haziz, F.; Clive, C.; Haswell, S.J.; Jones, I.M. Normal prion protein has an activity like that of superoxide dismutase. *Biochem. J.* 1999, 344, 1–5. [CrossRef] [PubMed]

122. Brown, D.R.; Schulz-Schaeffer, W.J.; Schmidt, B.; Kretzschmar, H.A. Prion protein-deficient cells show altered response to oxidative stress due to decreased SOD-1 activity. *Exp. Neurol.* 1997, 146, 104–112. [CrossRef] [PubMed]

123. Sakudo, A.; Lee, D.-c.; Saeki, K.; Nakamura, Y.; Inoue, K.; Matsumoto, Y.; Itohara, S.; Onodera, T. Impairment of superoxide dismutase activation by N-terminally truncated prion protein (PrP) in PrP-deficient neuronal cell line. *Biochem. Biophys. Res. Commun.* 2003, 308, 660–667. [CrossRef]

124. Guentchev, M.; Voigtländer, T.; Haberer, C.; Groschup, M.H.; Budka, H. Evidence for oxidative stress in experimental prion disease. *Neurobiol. Dis.* 2000, 7, 270–273. [CrossRef]

125. Klamt, F.; Dal-Pizzol, F.; Conte da Frota, M.L.; Walz, R.; Andrades, M.E.; Silva, E.G. Imbalance of antioxidant defense in mice lacking cellular prion protein. *Free Radic. Biol. Med.* 2001, 30, 1137–1144. [CrossRef]

126. Liow, B.S.; Liu, T.; Li, R.; Pan, T.; Petersen, R.B.; Smith, M.A.; Gambetti, P.; Perry, G.; Manson, J.C.; Brown, D.R.; et al. Increased levels of oxidative stress markers detected in the brains of mice devoid of prion protein. *J. Neurochem.* 2001, 76, 565–572. [CrossRef]

127. McLennan, N.F.; Brennan, P.M.; McNeill, A.; Davies, I.; Fotheringham, A.; Rennison, K.A.; Ritchie, D.; Brannan, F.; Head, M.W.; Ironside, J.W. Prion protein accumulation and neuroprotection in hypocric brain damage. *Am. J. Pathol.* 2004, 165, 227–235. [CrossRef]

128. Brenna, S.; Altmeppen, H.C.; Mohammadi, B.; Rissiek, B.; Schlink, F.; Ludewig, P.; Krisp, C.; Schlüter, H.; Failla, A.V.; Schneider, C.; et al. Characterization of brain-derived extracellular vesicles reveals changes in cellular origin after stroke and enrichment of the prion protein with a potential role in cellular uptake. *J. Extracell. Vesicles* 2020, 9, 1809065. [CrossRef]
129. Puig, B.; Yang, D.; Brenna, S.; Altempepper, H.C.; Magnus, T. Show Me Your Friends and I Tell You Who You Are: The Many Facets of Prion Protein in Stroke. Cells 2020, 9, 1609. [CrossRef]

130. Zeng, L.; Zhou, W.; Wang, G. Cellular prion protein (PrPc) and its role in stress responses. Int. J. Clin. Exp. Med. 2015, 8, 8042–8050.

131. Mitsios, N.; Saka, M.; Krupinski, J.; Pennucci, R.; Sanfeliu, C.; Miguel Turu, M.; Gaffney, J.; Kumar, P.; Kumar, S.; Sullivan, M.; et al. Cellular prion protein is increased in the plasma and peri-infarcted brain tissue after acute stroke. J. Neurosci. Res. 2007, 85, 602–611. [CrossRef] [PubMed]

132. Weise, J.; Crome, O.; Sandau, R.; Schulz-Schaeffer, W.; Bähr, M.; Zerr, I. Upregulation of cellular prion protein (PrPc) after focal cerebral ischemia and influence of lesion severity. Neurosci. Lett. 2004, 372, 146–150. [CrossRef]

133. Shyu, W.-C. Overexpression of PrPC by adenovirus-mediated gene targeting reduces ischemic injury in a stroke rat model. J. Neurosci. 2005, 25, 8967–8977. [PubMed]

134. Spudich, A.; Frigg, R.; Kilic, E.; Kilic, Ü.; Oesch, B.; Raeber, A.; Bassetti, C.L.; Hermann, D.M. Aggravation of ischemic brain injury of brain cellular prion protein in an animal model of insulin resistance: Possible implication in increased prevalence of stroke in pre-diabetics/diabetics. Biochem. Biophys. Res. Commun. 2014, 448, 151–156. [CrossRef] [PubMed]

135. Weise, J.; Crome, O.; Sandau, R.; Schulz-Schaeffer, W.; Bähr, M.; Zerr, I. Upregulation of cellular prion protein (PrPc) after focal cerebral ischemia and influence of lesion severity. Neurosci. Lett. 2004, 372, 146–150. [CrossRef]

136. Pham, N.; Dhar, A.; Khalaj, S.; Desai, K.; Taghibiglou, C. Down regulation of brain cellular prion protein in an animal model. Brain Pathol. 2005, 15, 1232

137. Wang, V.; Chuang, T.-C.; Hsu, Y.-D.; Chou, W.-Y.; Kao, M.-C. Nitric oxide induces prion protein via MEK and p38 MAPK signaling. J. Cell Biol. 2005, 169, 3768–3785. [CrossRef] [PubMed]

138. Shyu, W.-C. Overexpression of PrPC by adenovirus-mediated gene targeting reduces ischemic injury in a stroke rat model. J. Neurosci. 2005, 25, 8967–8977. [PubMed]

139. Brazil, D.P.; Hemmings, B.A. Ten years of protein kinase B signalling: A hard Akt to follow. J. Alzheimer’s Dis. 2009, 18, 8042–8050. [CrossRef] [PubMed]

140. Chiarini, L.B.; Freitas, A.R.O.; Zanata, S.M.; Brentani, R.R.; Martins, V.R. Cellular prion protein transduces neuroprotective signals. EMBO J. 2002, 21, 3317–3326. [CrossRef] [PubMed]

141. Chiarini, L.B.; Freitas, A.R.O.; Zanata, S.M.; Brentani, R.R.; Martins, V.R. Cellular prion protein transduces neuroprotective signals. EMBO J. 2002, 21, 3317–3326. [CrossRef] [PubMed]

142. Vassallo, N.; Herms, J.; Behrens, C.; Krebs, B.; Saeki, K.; Onodera, T.; Windl, O.; Kretzschmar, H.A. Activation of phosphatidylinositol 3-kinase by cellular prion protein and its role in cell survival. Biochem. Biophys. Res. Commun. 2005, 332, 75–82. [CrossRef] [PubMed]

143. Müller, S.A.; Stys, P.K.; Zamponi, G.W.; Tsutsumi, S. Cellular prion protein and NMDA receptor modulation: Protecting against excitotoxicity. Front. Cell Dev. Biol. 2014, 2, 2. [CrossRef] [PubMed]

144. Lopes, M.H.; Hajj, G.N.; Muras, A.G.; Mancini, G.L.; Castro, R.M.; Ribeiro, K.C.; Brentani, R.R.; Linden, R.; Martins, V.R. Interaction of cellular prion and stress-inducible protein 1 promotes neuritogenesis and neuronal survival. Mol. Cell. Neurosci. 2003, 22, 227–233. [CrossRef] [PubMed]

145. Chen, S.; Mangé, A.; Dong, L.; Lehmann, S.; Schachner, M. Prion protein as trans-interacting partner for neurons is involved in neurite outgrowth and neuronal survival. Mol. Cell. Neurosci. 2003, 22, 227–233. [CrossRef] [PubMed]

146. Lopes, M.H.; Hajj, G.N.; Muras, A.G.; Mancini, G.L.; Castro, R.M.; Ribeiro, K.C.; Brentani, R.R.; Linden, R.; Martins, V.R. Interaction of cellular prion and stress-inducible protein 1 promotes neuritogenesis and neuronal survival. Mol. Cell. Neurosci. 2003, 22, 227–233. [CrossRef] [PubMed]

147. Crestini, A.; Santilli, F.; Martellucci, S.; Carbone, E.; Sorice, M.; Piscopo, P.; Mattei, V. Prions and Neurodegenerative Diseases: A Focus on Alzheimer’s Disease. J. Alzheimer’s Dis. 2022, 85, 503–518. [CrossRef] [PubMed]

148. Santucci, A.; Sytnyk, V.; Leshchyns’ka, I.; Schachner, M. Prion protein recruits its neuronal receptor NCAM to lipid rafts to activate p59 fyn and to enhance neurite outgrowth. J. Cell Biol. 2005, 169, 341–354. [CrossRef] [PubMed]

149. Cheung, H.H.; Takagi, N.; Teves, L.; Logan, R.; Wallace, M.C.; Gurd, J.W. Altered association of protein tyrosine kinases with postsynaptic densities after transient cerebral ischemia in the rat brain. J. Cereb. Blood Flow Metab. 2000, 20, 505–512. [CrossRef] [PubMed]

150. Briner, A.; Götz, J.; Polanco, J.C. Fyn Kinase Controls Tau Aggregation In Vivo. Cell Rep. 2020, 32, 108045. [CrossRef] [PubMed]

151. Santucci, A.; Sytnyk, V.; Leshchyns’ka, I.; Schachner, M. Prion protein recruits its neuronal receptor NCAM to lipid rafts to activate p59 fyn and to enhance neurite outgrowth. J. Cell Biol. 2005, 169, 341–354. [CrossRef] [PubMed]

152. Cheung, H.H.; Takagi, N.; Teves, L.; Logan, R.; Wallace, M.C.; Gurd, J.W. Altered association of protein tyrosine kinases with postsynaptic densities after transient cerebral ischemia in the rat brain. J. Cereb. Blood Flow Metab. 2000, 20, 505–512. [CrossRef] [PubMed]

153. Takagi, N.; Cheung, H.H.; Bissoin, N.; Teves, L.; Wallace, M.C.; Gurd, J.W. The effect of transient global ischemia on the interaction of Src and Fyn with the N-methyl-D-aspartate receptor and postsynaptic densities: Possible involvement of Src homology 2 domains. J. Cereb. Blood Flow Metab. 1999, 19, 880–888. [CrossRef] [PubMed]

154. Knox, R.; Jiang, X. Fyn in Neurodevelopment and Ischemic Brain Injury. Dev. Neurosci. 2015, 37, 311–320. [CrossRef] [PubMed]

155. Paul, R.; Zhang, Z.G.; Eliceiri, B.P.; Jiang, Q.; Boccia, A.D.; Zhang, R.L.; Chopp, M.; Chershis, D.A. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat. Med. 2001, 7, 222–227. [CrossRef] [PubMed]
Sydow, A.; Mandelkow, E.M. ‘Prion-Like’ Propagation of Mouse and Human Tau Aggregates in an Inducible Mouse Model of Tauopathy. *Neurodegener. Dis.* 2010, 7, 28–31. [CrossRef] [PubMed]

Guo, J.L.; Lee, V.M.-Y. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. *J. Biol. Chem.* 2011, 286, 15317–15331. [CrossRef] [PubMed]

Clavaguera, F.; Akatsu, H.; Fraser, G.; Crowther, R.A.; Frank, S.; Hench, J.; Probst, A.; Winkler, D.T.; Reichwald, J.; Staufenbiel, M.; et al. Brain homogogenates from human tauopathies induce tau inclusions in mouse brain. *Proc. Natl. Acad. Sci. USA* 2013, 110, 9535–9540. [CrossRef] [PubMed]

Takahashi, R.H.; Yokotsuka, M.; Tobiume, M.; Sato, Y.; Hasegawa, H.; Nagao, T.; Gouras, G.K. Accumulation of cellular prion protein within β-amyloid oligomer plaques in aged human brains. *Brain Pathol.* 2021, 31, e12941. [CrossRef]

Aulić, S.; Maserpone, L.; Narkiewicz, J.; Isopi, E.; Bistaffa, E.; Ambrosetti, E.; Pastore, B.; De Cecco, E.; Scaini, D.; Zago, P. α-Synuclein amyloids hijack prion protein to gain cell entry, facilitate cell-to-cell spreading and block prion replication. *Sci. Rep.* 2017, 7, 1–12. [CrossRef]

Haas, L.T.; Salazar, S.V.; Kostylev, M.A.; Um, J.W.; Kaufman, A.C.; Strittmatter, S.M. Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer’s disease. *Brain A J. Neurol.* 2016, 139, 526–546. [CrossRef]

Hachty, N.; Fulek, M.; Zajaczkowska, K.; Kurpas, D.; Trypka, E.; Leszek, J. Cellular Prion Protein and Amyloid-β Oligomers in Alzheimer’s Disease—There Are Connections? *Preprints* 2021, 2021050032. [CrossRef]

Kostylev, M.A.; Tuttle, M.D.; Lee, S.; Klein, L.E.; Takahashi, H.; Cox, T.O.; Gunther, E.C.; Zilm, K.W.; Strittmatter, S.M. Liquid and Hydrophagel Phases of PrPSc Linked to Conformation Shifts and Triggered by Alzheimer’s Amyloid-β Oligomers. *Mol. Cell. Biol.* 2018, 72, 426–443.e142. [CrossRef]

Um, J.W.; Kaufman, A.C.; Kostylev, M.; Heiss, J.K.; Stagi, M.; Takahashi, H. Metabotropic glutamate receptor 5 is a coreceptor for alzheimer Aβ oligomer bound to cellular prion protein. *Neuron* 2013, 79, 887–902. [CrossRef]

Rushworth, J.V.; Griffiths, H.H.; Watt, N.T.; Hooper, N.M. Prion protein-mediated toxicity of Amyloid-β Oligomers Requires Lipid Rafts and the Transmembrane LRPI. *J. Biol. Chem.* 2013, 288, 8935–8951. [CrossRef]

Mattei, V.; Manganelli, V.; Martellucci, S.; Capozzi, A.; Mantuano, E.; Longo, A.; Ferri, A.; Garofalo, T.; Sorice, M.; Misasi, R. A multimolecular signaling complex including PrP(C) and LRP1 is strictly dependent on lipid rafts and is essential for the function of tissue plasminogen activator. *J. Neurochem.* 2020, 152, 468–481. [CrossRef] [PubMed]

Lauren, J.; Gimbel, D.A.; Nygaard, H.B.; Gilbert, J.W.; Strittmatter, S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. *Nature* 2009, 457, 1128–1132. [CrossRef] [PubMed]

Kessels, H.W.; Nguyen, L.N.; Nabavi, S.; Surewicz, K.; Zajkowski, T.; Surewicz, W.K.; Nieznanski, K. Identification of prion protein-α-synuclein amyloids. *Acta Neuropathol.* 2020, 140, 887–902. [CrossRef]

Calella, A.M.; Farinelli, M.; Nuvolone, M.; Mirante, O.; Moos, R.; Falsig, J.; Mansuy, I.M.; Aguzzi, A. Prion protein and Aβ-related synaptic toxicity impairment. *EMBO Mol. Med.* 2010, 2, 306–314. [CrossRef]

Mengel, D.; Hong, W.; Corbett, G.T.; Liu, W.; DeSousa, A.; Solforosi, L.; Fang, C.; Frosch, M.P.; Collinge, J.; Harris, D.A.; et al. PrP-grafted antibodies bind certain amyloid β-protein aggregates, but do not prevent toxicity. *Brain Res.* 2019, 1710, 125–135. [CrossRef]

Chen, S.; Yadav, S.P.; Surewicz, W.K. Interaction between human prion protein and amyloid-β (Aβ) oligomers: Role of N-terminal residues. *J. Biol. Chem.* 2010, 285, 26377–26383. [CrossRef] [PubMed]

De Cecco, E.; Legname, G. The role of the prion protein in the internalization of α-synuclein amyloids. *Pion* 2018, 12, 23–27. [CrossRef]

Gomes, L.A.; Hipp, S.A.; Upadhyaya, A.R.; Balakrishnan, K.; Ospitalieri, S.; Koper, M.J.; Largo-Barrientos, P.; Uytterhoeven, V.; Reichwald, J.; Rabe, S. Aβ-induced acceleration of Alzheimer-related τ-pathway spreading and its association with prion protein. *Acta Neuropathol. 2019*, 138, 913–941. [CrossRef]

De Cecco, E.; Celaurio, L.; Vanni, S.; Grandolfo, M.; Bistaffa, E.; Moda, F.; Aguzzì, A.; Legname, G. The uptake of tau amyloid fibrils is facilitated by the cellular prion protein and hampers prion propagation in cultured cells. *J. Neurochem.* 2020, 155, 577–591. [CrossRef]

Rosenberger, U.K.; Harmeier, A.; Woerner, A.C.; Goodman, J.L.; Muller, V.; Krishnan, R. The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication. *EMBO J.* 2011, 30, 2057–2070. [CrossRef] [PubMed]

Nieznanski, K.; Choi, J.K.; Chen, S.; Surewicz, K.; Surewicz, W.K. Soluble prion protein inhibits amyloid-β (Aβ) fibrillization and toxicity. *J. Biol. Chem.* 2012, 287, 33104–33108. [CrossRef]

Nieznanski, H.; Bandyszewska, M.; Surewicz, K.; Zajkowski, T.; Surewicz, W.K.; Nieznanski, K. Identification of prion protein-derived peptides of potential use in Alzheimer’s disease therapy. *Biochim. Biophys. Acta Mol. Basis Dis.* 2018, 1864, 2143–2153. [CrossRef] [PubMed]
205. Béland, M.; Bédard, M.; Tremblay, G.; Lavigne, P.; Roucou, X. Aβ induces its own prion protein N-terminal fragment (PrPN1)–mediated neutralization in amorphous aggregates. *Neurobiol. Aging* 2014, 35, 1537–1548. [CrossRef]

206. Heiseke, A.; Schöbel, S.; Lichtenthaler, S.F.; Vorberg, I.; Guschup, M.H.; Kretzschmar, H.; Schätzl, H.M.; Nunziante, M. The Novel Sorting Nexin SNX33 Interferes with Cellular PrPSc Formation by Modulation of PrPSc Shedding. *Traffic* 2008, 9, 1116–1129. [CrossRef] [PubMed]

207. Rösener, N.S.; Gremer, L.; Reinartz, E.; König, A.; Brener, O.; Heise, H.; Hoyer, W.; Neudecker, P.; Willbold, D. A d-enantiomeric peptide interferes with heteroassociation of amyloid-β oligomers and prion protein. *J. Biol. Chem.* 2018, 293, 15748–15764. [CrossRef] [PubMed]